Idiopathic Inflammatory Myopathies
|
|
- Cornelius Dean
- 6 years ago
- Views:
Transcription
1 62 SUPPLIMENT TO JAPI JUNE 2006 VOL. 54 Idiopathic Inflammatory Myopathies Ashok Kumar Definition The idiopathic inflammatory myopathies (IIM) are nonsuppurative muscle disorders which are characterised by symmetrical, proximal muscle weakness, decreased muscle endurance and chronic inflammation in muscle tissue. 1 Epidemiology IIMs are rare disorders (estimated incidence: 5 to 10 per million per year). A bimodal age of onset (10-15 years and years) has been reported. Female to male ratio is 2:1 except in inclusion-body myositis where it is reversed. Prevalence of the disease is the highest in the Japanese and the lowest in blacks. HLA associations include B8, DR3 and DRW52. Pathophysiology The molecular basis of muscle weakness in myositis is not yet known. Even the degree of inflammation observed histopathologically bears no direct relation with the extent of weakness. 2,3 The significance of replacement of muscle tissue by fat is also not clear. 4 Role of factors other than inflammation is strongly suspected because of abnormalities of energy metabolism as revealed by reduced levels of phosphocreatine (PCr) and adenosine triphosphate (ATP) on magnetic resonance spectroscopy. 5-7 Diagnostic criteria The generally accepted criteria for diagnosis of IIM include: 8 1. Proximal muscle weakness 2. Elevated levels of muscle enzymes (CPK, LDH, aldolase, AST, ALT) 3. Myopathic changes demonstrated on electromyography 4. Muscle biopsy evidence of inflammation. The addition of a skin rash (Criterion 5) allows the diagnosis of dermatomyositis Differential Diagnosis Although classical presentation of dermatomyositis hardly has any differential diagnosis, a long list of conditions needs to be considered in the differential diagnosis of polymyositis. These include drug-induced myopathies, endocrinopathies, paraneoplastic myopathy, pyomyositis, parasitic myositis, muscle dystrophies, metabolic myopathies, myasthenia gravis, Lambert-Eaton syndrome, Guillaine-Barre syndrome, spinal muscular atrophies, amyotrophic lateral sclerosis, etc. Important drugs which are known to cause myopathy include Professor of Medicine & Head, Clinical Immunology and Rheumatology Service, AIIMS, New Delhi glucocorticoids, d-penicillamine, zidovudine, cholesterollowering drugs (clofibrate and statins) and chloroquine. Classification Table 1 gives the clinical classification currently favoured. Another classification, based on myositis-specific autoantibodies (MSAs) is given in Table 2. MSAs identify relatively homogeneous groups of patients with IIM. The significance of this classification is diminished by the fact that MSAs occur only in about 35% of patients. 10 Group I Group II Group III Group IV Group V Group VI Table 1 : Clinical classification of the idiopathic inflammatory myopathies Idiopathic polymyositis in adults (PM) Idiopathic dermatomyositis in adults (DM)* DM/PM associated with malignancy Childhood associated DM/PM DM/PM associated with CTD Inclusion body myositis (IBM) *Also includes amyopathic dermatomyositis Table 2 : Classification based on myositis-specific autoantibodies 10 Autoantibody Clinical features HLA Treatment response Antisynthetase Anti-SRP Anti-Mi2 PM or DM with relatively acute-onset Interstitial lung disease, Fever, Arthritis, Raynaud s phenomenon PM with very acute onset, often in fall, Severe weakness, Palpitations DM with V sign, shawl sign and cuticular overgrowth DR3, DRw- 52 DR5, DRw52 DR7, DRw53 Moderate with disease persistence Poor Good Clinical Features Typically, patients present with a recent-onset (a few weeks to months) difficulty in getting up from chair, climbing stairs, lifting objects and combing hair. The ocular muscles are never involved. The facial and distal muscles are spared in the majority. Neck-drop (weakness of neck-flexors) and dysphagia (weakness of pharyngeal muscles) are frequent features. Advanced cases may develop weakness of respiratory muscles. Myalgia and muscle tenderness is quite uncommon. In the author s series (76 cases), dermatomyositis was the commonest subset (47%), followed by CTD-associated group (29%) and idiopathic PM (17%). IBM is exceedingly rare in India. Juvenile dermatomyositis is not as rare but under-reported from India. 11,12 Table 3 gives a comparative account of demographic and clinical features. Two Indian
2 SUPPLIMENT TO JAPI JUNE 2006 VOL Parameters Table 3 : Demographic and clinical features in patients with IIM Author s series (unpublished data) Prasad et al 13 Chowdhary et al 14 Love et al 15 Hausmanowa et al 16 Number of patients Mean age at diagnosis F:M 2.8:1 1.3:1 2:1 2:1 4:1 Ethnicity North Indian North Indian North Indian While Americans Polish Arthritis 40% 37% 55% 47% 70% Raynaud s 18% NA 24% 35% 41% ILD 8% NA 8% 29% 18% Fever 28% NA 65% 37% 39% Weight loss NA NA 47% NA 42% DM rash 41% 42% 39% 27% 37% Dysphagia 38% 48% NA NA NA Dyspnoea 10% NA NA NA NA Table 4 : Comparison of dermatomyositis with polymyositis Characteristic Dermatomyositis Polymyositis Age-group All age groups Mainly adults Overlap with SLE/SSc Overlap with other autoimmune disease Infrequent Association with cancer 15% Debatable Viral aetiology Not proven HIV, HTLV-1 Drug-induced Rare Well known series are also included for comparison Clinical features of dermatomyositis and polymyositis are compared in Table 4. Table 5 gives the serological profile of IIMs, including MSAs MSA-based subsets have not been identified in Indian population. The data are grossly inadequate and more work is needed in this area. Significant HLA associations were found in the author s series, with DR3 and B8. Laboratory Investigations Despite their limitations, muscle biopsy, electromyography and muscle enzyme levels (particularly, CPK) are useful in establishing the diagnosis of an inflammatory myopathy. In order to assess the response to treatment, one needs to reliably test the activity of disease. For this purpose, numerous clinical instruments have been described but all suffer from drawbacks Laboratory plays a supplementary role in discriminating between active and chronic disease. ESR and other acute-phase reactants are not useful in the evaluation of IIM. 23 Similarly, limitations of muscle enzymes such as CPK when used alone to measure disease activity are well known Serum CPK levels are also influenced by exercise. 27 Although muscle histology can provide useful information on the disease activity, the currently used technique of open muscle biopsy can not be recommended for monitoring purposes. In the research setting this problem has been overcome with the use of a conchotome. This semi-open technique can be used with little discomfort to the patient for performing repeated biopsies. 28 Magnetic Resonance Imaging MRI provides a non-invasive but expensive modality of diagnosis and assessment of disease activity. However, it can not replace muscle biopsy for the diagnosis of IIM. In follow-up studies, a strong correlation was observed between increased T2 and STIR signal intensity and disease activity Magnetic Resonance Spectroscopy (MRS) And Ultrasound Phosphorus MRS, assesses muscle bioenergetic metabolites such as phosphocreatine (PCr) and ATP. In active dermatomyositis, levels of these metabolites are reduced, while the ratio of inorganic phosphate (Pi) to PCr (Pi/PCr) is increased relative to controls. Exercise accentuates these abnormalities further. 31,32 MRS abnormalities underscore the significance of metabolic disturbances in the pathogenesis of the muscle weakness and point to the need for therapies other than immunosuppressants. Muscle bioenergetic defects have been shown to precede other changes and even persist after resolution of inflammation. 32,34 Proton MRS determines lipid-to-water ratio in the muscle. In the active stage of dermatomyositis, the ratio was found abnormally low and it rose markedly at 3 months of treatment. 35 Urinary proton MRS metabolic profiles may also have the potential to be a non-invasive method for assessment of disease activity in IIM patients. Ultrasound does not seem to be helpful because muscle echogenicity bears no correlation with muscle strength. Management Corticosteroids are the mainstay of treatment of this disease even though their use is not based on rigorous scientific evidence. A starting dose of prednisone of 0.75 mg/kg/day (which corresponds to mg/day) is recommended. 36 There are no data to show that higher doses are associated with superior outcome. Tapering could be started when a normal or close to normal muscle function has been achieved (usually, after 4-12 weeks), irrespective of
3 64 SUPPLIMENT TO JAPI JUNE 2006 VOL. 54 Table 5 : Serological features of patients with IIM Parameters Authors series (unpublished data) [n = 76] Chowdhary et al 12 [n = 22] Love et al 13 [n = 2I2] Hausmanowa et al 14 [n = 84] Brouwer et al 15 [n = 417] ANA 50% 22% 52% NA NA UIRNP ND 4% 11% 4% 6% Sm ND 4% 3% 0% Ro ND 23% 12% 14% 25% La ND 14% 8% 0% 5% Pm-Scl ND 4% 2% 24% 6% MSA 30%+ 31% 31% 19% 38% Anti-synthetase a. Anti-Jo-1 b. Others 30% 5% 25% 18% 14% 4% 23% 17% 6% 13% 11% 2% 21% 18% 3% Anti-SRP ND 4% 3% 1% 5% Anti-Mi-2 ND 9% 5% 5% 14% ND = not done NA - not available CPK levels. Tapering of corticosteroids should be begun at the rate of 10 mg reduction/month, initially. When a dose of 20 mg/day is reached, the reduction should be more gradual. Maintenance dosage of 5-15 mg/day is often required for several years. An attempt to withdraw should be made after 2-3 years. 37 Significant clinical improvement is noted in 60-80% of the patients There are two situations in which other immunosuppressives are required: steroid-resistant cases (about 30%) and steroidresponsive patients who develop major adverse effects. 41 In both situations azathioprine (2.5 mg/kg/day) has been found to be useful. 42 A combination of oral methotrexate with azathioprine may prove beneficial in refractory cases. 43 IVIG was found beneficial in treatment-resistant dermatomyositis patients but its role in polymyositis remains controversial. 44 Plasmapheresis had no positive effect compared to corticosteroids alone in a controlled trial. 45 Open studies and case reports indicate a beneficial effect of methotrexate ( mg/week administered orally, i.m., or up to 100 mg/week i.v.) in steroid-resistant cases. 45,47 The effect of cyclophosphamide in IIM is more controversial. There are scant data on the beneficial effects of cyclosporin A in adults with refractory IIM. The effect is often seen within a few weeks of treatment. In IBM, it is still controversial whether immunosuppressive drugs have a beneficial effect. Some authorities advocate a combination of steroids and other immunosuppressants from the start of therapy. 36,48 Physical Exercise And Rehabilitation For a long time, there have been few advocates of physical exercise in the management of IIMs because of fear of causing disease flare-ups. Recent studies however, have demonstrated the safety and usefulness of active exercise in stable IIM. 49,50 Active physical exercises such as mild aerobic programme on a bicycle or in the pool can be introduced when disease activity begins to subside. 51 Prognosis The IIM are serious disorders with as many as two-thirds of patients developing residual functional impairment in the long-term. 52,53 Conclusions IIMs are a challenging group of muscle disorders both from the pathogenetic and therapeutic standpoint. Recent work from NIH, USA has shed some light on their immunopathogenesis. A new classification based on myositisspecific autoantibodies has been proposed which represents a substantial advance in this area. However, MSAs are found only in 35-40% of patients. Thus, large lacunae remain in our current understanding of these disorders. The use of MRS to assess metabolic abnormalities may throw some light in this regard and also serve as a means of disease activity assessment. On the therapeutic front, there is paucity of hard scientific evidence with regard to the best treatment. Considering the high frequency of sequelae of disease and substantial mortality, some authorities have recommended combinations of steroids and immunosuppressive drugs from the start. Active physical exercises have an important role in the management of IIM once the activity of disease is brought under reasonable control. The present treatment protocols for IIM are based on experience gained from uncontrolled clinical trials. Many patients suffer from serious side effects of steroid therapy. There is an urgent need for developing a validated disease activity measure and performing controlled trials to develop better treatment strategies. There is also a need to develop molecular approaches to the treatment of IIM similar to those developed for rheumatoid arthritis. Another important area, which needs to be explored, is the possible metabolic disturbance in IIM as a cause of the persisting muscle weakness.
4 SUPPLIMENT TO JAPI JUNE 2006 VOL References 1. Dalakas MC. Polymyositis. dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325: Bunch TW. Worthington JW. Combs JJ. IIstrup DM. Engel AG. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980:92: Kroll M, Otis J, Kagen L. Serum enzyme myoglobin and muscle strength relationships in polymyositis and dermatomyositis. J Rheumatol 1986:13: Lundberg I, Kartz A-K, Nennesmo I, Andersson U, Klareskog L. Effects of corticosteroid treatment on IL-1 and ILβ expression in muscle tissue in patients with inflammatory myopathies. Arthritis Rheum 1997;40S Newman ED, Kurland RJ. P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Arthritis Rheum 1992;35: Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL. Price RR, et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994;37: Chung YL, Smith EC, Williams SCR, et al. In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: A preliminary study. Eur J Med Res 1997:2: Bohan A, Peter JB, Polymyositis and dermatomyositis: First of two parts. N Engl J Med 1975;292: Wortmann RL. Inflammatory diseases of the muscle and other myopathies. In : Kelley WN. Harris ED Jr. Ruddy S. Sledgc CB (Eds): Textbook of Rheumatology. 5th Edition. Philadelphia. WB Saunders Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20: Seth V, Kabra SK, Semwal OP, Jain Y. Juvenile dermatomyositis. Indian J Pediatr 1996;63: Singh S, Kumar L, Shankar KR. Juvenile dermatomyositis in north India.Indian Pediatr 1997;34: Prasad ML, Sarkar C, Roy S, et al. Idiopathic inflammatory myopathy: clinico-pathological observations in the Indian population. Brit J Rheumatol 1992;31: Chowdhary V, Aggarwal A, Misra R. Prevalence and clinical association of myositis-specific autoantibodies in North Indian patients with idiopathic inflammatory myopathy. APLAR J Rheumatol Love LA. LefTRL, Frascr DD, et al. A new approach to classification of idiopathic inflammation myopathies: Myositisspecific autoantibodies define useful homogeneous patients groups. Medicine (Baltimore) 1991;70: Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al Clinical, serologic and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40: Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60: Daniels L, Worthingham C. Muscle testing. 4th edn. Philadelphia: WB Saunders Helewa A. Goldsmith CH. Smythe HA. The modified sphygmomanometer An instrument to measure muscle strength: A validation study. J Chron Dis 1981;34: Stroll T, Brühlmann P, Stucki G, Seifert B, Michel BA. Muscle strength assessment in polymyositis and dermatomyositis: evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol 1995;22: Csuka M. McCarty DJ. Simple method for measurement of lower extremity muscle strength. Am J Med 1985;78: Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996;23: Barwick DD, Walton JN. Polymyositis Am J Med 1963;35: Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. Am J Med 1986;80: Adams EM. Plotz PH. The treatment of myositis. Rheum Dis Clin North Am 1995;21: Rose AL, Walton JN, Polymyositis: A survey of 89 cases with particular reference to treatment and prognosis. Brain 1966;89: Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;86: Noakes TD. Effect of exercise in serum enzymes activities in humans. Sports Med 1987;4: Lundberg IE, Dorph C, Nennesmol. Percutaneous conchotome technique A valuable and safe procedure for muscle biopsies. Arthritis Rheum 1998;1024:S Fraser DD, Frank JA, Dalakas Miller FW, Ricks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18: Reimers CD, Schedel H, Fleckenstein JL, et al. Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 1994;241: Kaufman LD, Gruber BL, Gerstman DP, Kaell AT. Preliminary observation on the role of magnetic resonance imaging for polymyositis and dermatomyositis. Ann Rheumatol Dis 1987;46: Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL. Price RR, et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994;37: Kaufman LD, Gruber BL, Gerstman DP, Kaell AT. Preliminary observation on the role of magnetic resonance imaging for polymyositis and dermatomyositis. Ann Rheumatol Dis 1987;46: Kari S, Olsen NJ, Park JH. Evaluation of muscle diseases using artificial neural network analysis of 31P MR spectroscopy data. Magn Reson Med 1995;34: Chung YL. Wassif WS. Bell D, et al. Urinary assessment of disease activity in polymyositis by in vitro NMR Proceedings of the International Society for Magnetic Resonance in Medicine 1996;2: Lundberg I, Chung YL. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology 2000;39: Rose AL, Walton JN. Polymyositis: A survey of 89 cases with particular reference to treatment and prognosis. Brain 1966;89: Vignos PJ, Bowling GF, Watkins MP. Polymyositis Arch Intern Med 1964;114: Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;86: Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990 diagnosis, treatment and prognosis. Prog Neurobiol 1990;35: Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis. Acta Ncurol Scand 1982;65:
5 66 SUPPLIMENT TO JAPI JUNE 2006 VOL Bunch TW. Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981:24: Villalba L, Hicks JE, Adams EM et al. Treatment of refractory myositis. Arthritis Rheum 1998:41: Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: Miller FW, Leitman SF, Cronia ME. Controlled trial of plasma exchange and leucapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326: Malaviya AN, Many R, Schunong RS. Treatment of dermatomyositis with methotrexate. Lancet 1968;2: Metzgcr AL, Bohan A, Goldberg LS, Bluestonc R, Pearson CM. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Ann Intern Med 1974;81: Adams EM, Plotz PH. The treatment of myositis. Rheum Dis Clin North Am 1995;21: Alexanderson H, Stenstrom C, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 1999;38: Wiesinger GF, Quittan M, Aringer M, et al. Improvement of physical fitness and muscle strength in polymyositis/ dermatomyositis patients by a training programme. Br J Rheumatol 1998;37: Hicks JE. Role of rehabilitation in the management of myopathies. Curr Opin Rheumatol 1998;10: Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis. Acta Neurol Scand 1982;65: Thymms KE, Webb J. Dermatomyositis and other connective tissue diseases. A review of 105 cases. J Rheumatol 1985;12:
Autoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
More informationIdiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya
Idiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya I.W, 28 YRS, FEMALE SHOP STEWARD Referred to KNH on 16/06/09 from Thika Nursing Home Weakness
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationWhat your autoantibodies tell us about your disease. Mark Gourley, MD
What your autoantibodies tell us about your disease Mark Gourley, MD The Importance of the Immune System Defends us against foreign invaders Self (cancer) and Nonself (virus, bacteria, etc.) But, if the
More informationIdiopathic inflammatory myopathies
Myositis and cancer Idiopathic inflammatory myopathies Primary idiopathic polymyositis Primary idiopathic dermatomyositis Juvenile poly/dermatomyositis Myositis associated with another CTD Myositis associated
More informationThe many faces of myositis. Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands
The many faces of myositis Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands Outline of the presentation Classification Diagnosis Therapy Prognosis Diagnostic criteria
More informationInflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist
Inflammatory Myopathies 4 th year MBBS Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist Case A 64 woman presents with erythematous itchy rash over back of hands & forehead. For 1 month
More informationOverview of Diagnostic Autoantibodies in Inflammatory Myopathy
Overview of Diagnostic Autoantibodies in Inflammatory Myopathy Minoru Satoh, M.D., Ph.D. Research Associate Professor of Medicine Division of Rheumatology and Clinical Immunology University of Florida
More informationArthritis Superspeciality Center, Hubli, Karnataka and 2 Department of Rheumatology, SDM Medical College, Dharwad, Karnataka, India.
JOURNAL OF CASE REPORTS 2015;5(1):147-151 A Rare Case of Juvenile Dermatomyositis Vikram Haridas 1,2, Kiran Haridas 1 1,2 Arthritis Superspeciality Center, Hubli, Karnataka and 2 Department of Rheumatology,
More informationDiscovery, Understanding, and Progress in Myositis
Discovery, Understanding, and Progress in Myositis Steven Ytterberg, M.D. TMA Annual Patient Conference New Orleans, LA Sept. 2, 2016 Disclosures Financial: Dynavax Corp. Pfizer Mallinckrodt American Board
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationRheumatology E-learning. University of Szeged Department of Rheumatology and Immunology
Rheumatology E-learning University of Szeged Department of Rheumatology and Immunology Introduction Idiopathic inflammatory myopathies (IIM) are a group of systemic diseases characterized by an immune
More informationMyositis 101. Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic, Rochester, MN
Myositis 101 Steven R. Ytterberg, M.D. Rheumatology Mayo Clinic, Rochester, MN Myositis Association Annual Conference Louisville, KY Sept. 6 & 7, 2018 Disclosures Consulting: Dynavax Pfizer Off-label use:
More informationPOLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by
POLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by infections, drugs, toxins Definition Epidemiology Pathogenesis
More informationCase Report Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
Case Reports in Rheumatology Volume 2016, Article ID 9068061, 4 pages http://dx.doi.org/10.1155/2016/9068061 Case Report Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
More informationIDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS. Franclo Henning Division of Neurology Tygerberg Hospital
IDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS Franclo Henning Division of Neurology Tygerberg Hospital Classification systems Clinical (Bohan and Peter) Clinico-pathological (Dalakas & others)
More informationHUNGARIAN MYOSITIS COHORT
CLINICAL ADVANCES OF ANTI- TIF1Γ AUTOANTIBODY IN A HUNGARIAN MYOSITIS COHORT Melinda Nagy-Vincze 1, Zoltán Griger 1, Levente Bodoki 1, Zsuzsa Szankai 1, Zoe E. Betteridge 2, Katalin Dankó 1 1 University
More informationFunctional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?
Hypothalamus-pituitary-adrenocortical and -gonadal axis in Endothelial RA / M. Cutolo cell activation induced by ANCA? / A.C. Muller EDITORIAL Kobold et al. Functional outcome of myositis patients: Can
More informationFavorable rituximab response in patients with refractory idiopathic inflammatory myopathies
de Souza et al. Advances in Rheumatology (2018) 58:31 https://doi.org/10.1186/s42358-018-0030-z Advances in Rheumatology RESEARCH Favorable rituximab response in patients with refractory idiopathic inflammatory
More informationIdiopathic inflammatory myopathies excluding inclusion body myositis
Idiopathic inflammatory myopathies excluding inclusion body myositis Marianne de Visser, Dept. of Neurology, Academic Medical Centre, Amsterdam, The Netherlands The idiopathic inflammatory myopathies (IIMs),
More informationDisease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis
Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis H. Alexanderson 1,2, I.E. Lundberg 2 1 Department of Physical Therapy, Rheumatology Unit and 2 Rheumatology
More informationSignificance of antibody testing in idiopathic inflammatory myopathies
2/0/20 Significance of antibody testing in idiopathic inflammatory myopathies Jiří Vencovský Institute of Rheumatology, Prague Diagnosis Polymyositis Juvenile DM (JPM) Paraneoplastic Myositis in overlap
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Rituximab for the treatment of dermatomyositis and polymyositis (Adults) Reference: NHS England A13X05/01 Information Reader Box (IRB) to be inserted on inside
More informationAutoantibodies andprognosis. Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic
Autoantibodies andprognosis Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic HeterogeneityofIIMs Diagnosis Polymyositis Dermatomyositis IBM Necrotising myopathy Paraneoplastic Amyopathic
More informationRituximab Therapy for Myopathy Associated With Anti Signal Recognition Particle Antibodies: A Case Series
Arthritis Care & Research Vol. 62, No. 9, September 2010, pp 1328 1334 DOI 10.1002/acr.20219 2010, American College of Rheumatology ORIGINAL ARTICLE Rituximab Therapy for Myopathy Associated With Anti
More informationLong-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients
Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients C. Dobloug, R. Walle-Hansen, J.T. Gran, Ø. Molberg Section of Rheumatology,
More informationL. Nandini Moorthy, MD MS 2012
L. Nandini Moorthy, MD MS 2012 L Nandini Moorthy, MD MS 09 17 yo Ashkenazi male with proximal muscle pain and weakness, mild malar erythema and erythema over knees and dorsal aspect of PIPs Mild tenderness
More informationAutoantibodies in Idiopathic Inflammatory Myopathies. Vidya Limaye Rheumatology Department Royal Adelaide Hospital
Autoantibodies in Idiopathic Inflammatory Myopathies Vidya Limaye Rheumatology Department Royal Adelaide Hospital Idiopathic Inflammatory Myopathies (IIM) Heterogeneous group of systemic autoimmune syndromes
More information*Pari Basharat ABSTRACT OVERVIEW OF IDIOPATHIC INFLAMMATORY MYOPATHIES
IDIOPATHIC INFLAMMATORY MYOPATHIES: ASSOCIATION WITH OVERLAP MYOSITIS AND SYNDROMES: CLASSIFICATION, CLINICAL CHARACTERISTICS, AND ASSOCIATED AUTOANTIBODIES *Pari Basharat University of Western Ontario,
More informationIdiopathic Inflammatory Myopathy: Treatment Options
Idiopathic Inflammatory Myopathy: Treatment Options Stephen J. DiMartino, MD, PhD Corresponding author Stephen J. DiMartino, MD, PhD Weill Medical College, Cornell University; and Hospital for Special
More informationTools to Aid in the Accurate Diagnosis of. Connective Tissue Disease
Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,
More informationNovel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies Analysis of 100 French Canadian Patients Yves Troyanov, MD, Ira N. Targoff, MD, Jean-Luc
More informationDRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)
Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be
More informationE vidence for a significant myositis cancer association has
1345 EXTENDED REPORT The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis Hector Chinoy, Noreen Fertig, Chester V Oddis, William E R Ollier, Robert
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More informationMYOSITIS. A physician s guide to the
MYOSITIS A physician s guide to the TABLE OF CONTENTS Myositis basics... 1 contents... 3 Causes... 7... 11 Affected populations... 15 Diagnosis... 17... 25... 31 PHYSICIAN S GUIDE TO MYOSITIS matory
More informationSTUDIES ON INTERLEUKIN-1 IN IDIOPATHIC INFLAMMATORY MYOPATHIES
From the Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden STUDIES ON INTERLEUKIN-1 IN IDIOPATHIC INFLAMMATORY MYOPATHIES Christina Dorph Stockholm 2009 All previously
More informationIdiopathic inflammatory myopathies are a group of autoimmune
Approach to Diagnosis and Management of an Idiopathic Inflammatory Myopathy Case Study and Commentary, Carrie Edelman, MD Idiopathic inflammatory myopathies are a group of autoimmune diseases characterized
More informationPROGNOSTIC FACTORS IN POLYMY OSITIS/DERMATOMY OSITIS
PROGNOSTIC FACTORS IN POLYMY OSITIS/DERMATOMY OSITIS A Computer-Assisted Analysis of Ninety-Two Cases JOCHANAN BENBASSAT, DOV GEFEL, KEREN LARHOLT, SHAUL SUKENIK, VLADIMIR MORGENSTERN, and AVlNOAM ZLOTNlCK
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationClinical and serological characteristics of 125 Dutch myositis patients
J Neurol (2002) 249 : 69 75 Steinkopff Verlag 2002 ORIGINAL COMMUNICATION G. J. D. Hengstman R. Brouwer W. T. M. Vree Egberts H. P. Seelig P. J. H. Jongen W. J. van Venrooij B. G. M. van Engelen Clinical
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationThis month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.
February 20, 2017 Client Letter Test Update February 2017 Dear Colleague: This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma
More informationmyopathy and interstitial lung dise
NAOSITE: Nagasaki University's Ac Title Author(s) Citation A case of primary Sjögren's syndrom myopathy and interstitial lung dise Koga, Tomohiro; Kouhisa, Yukiko; Na Akinari; Motomura, Masakatsu; Kawak
More informationJUVENILE DERMATOMYOSITIS
JUVENILE DERMATOMYOSITIS - how to diagnose, how to treat? Miloš Nikolić, MD, PhD Professor and Chairman Department of Dermatology, Division of Pediatric Dermatology University of Belgrade, School of Medicine,
More informationDermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine
Dermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville Learning Objectives
More informationSCLERODERMA OVERLAP SYNDROME: A CASE REPORT Diwakar K. Singh 1, Nataraju H. V 2
SCLERODERMA OVERLAP SYNDROME: A Diwakar K. Singh 1, Nataraju H. V 2 HOW TO CITE THIS ARTICLE: Diwakar K. Singh, Nataraju H. V. Scleroderma Overlap Syndrome: A Case Report. Journal of Evolution of Medical
More informationComplex repetitive discharge on electromyography as a risk factor for malignancy in idiopathic inflammatory myopathy
ORIGINAL ARTICLE Korean J Intern Med 2014;29:814-821 Complex repetitive discharge on electromyography as a risk factor for malignancy in idiopathic inflammatory myopathy Na Ri Kim 1, Eon Jeong Nam 1, Jong
More informationClinical Study A Clinical Analysis of Risk Factors for Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myopathy
Clinical and Developmental Immunology Volume 2013, Article ID 648570, 4 pages http://dx.doi.org/10.1155/2013/648570 Clinical Study A Clinical Analysis of Risk Factors for Interstitial Lung Disease in Patients
More informationMortality in idiopathic inflammatory myopathies
Mortality in idiopathic inflammatory myopathies I.E. Lundberg 1, C.J. Forbess 2 1 Rheumatology Unit, Department of Medicine at Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm,
More informationI mmune mediated and inflammatory myopathies are usually
420 PAPER Myopathy with antibodies to the signal recognition particle: clinical and pathological features T Miller, M T Al-Lozi, G Lopate, A Pestronk... J Neurol Neurosurg Psychiatry 2002;73:420 428 See
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationClinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody
Cace report Clinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody Yoichiro Akiyama 1, Takao Nagashima 1, Masahiro Iwamoto
More informationPedsCases Podcast Scripts
Pedss Podcast Scripts This is a text version of a podcast from Pedscases.com on Juvenile Dermatomyositis. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationEvidence Review: Title. Month/ Year. Evidence Review:
Evidence Review: Title Month/ Year Evidence Review: Rituximab for connective tissue disease associated interstitial lung disease October 2014 Standard Operating Procedure: NHS England Evidence Review:
More informationClinical Laboratory. [None
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG
More informationClinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Rheumatoid Factor
More informationDiseases of Muscle and Neuromuscular Junction
Diseases of Muscle and Neuromuscular Junction Diseases of Muscle and Neuromuscular Junction Neuromuscular Junction Muscle Myastenia Gravis Eaton-Lambert Syndrome Toxic Infllammatory Denervation Atrophy
More informationDermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
CASE REPORT Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan Kenichiro Tokunaga 1 and Noboru Hagino 2 Abstract We performed a retrospective
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationMyosites du sujet âgé
Myosites du sujet âgé Olivier Benveniste Département de Médecine Interne Centre de Référence Maladies Neuro-Musculaires Equipe Muscle Inflammatoire U974 Groupe Hospitalier Pitié-Salpêtrière Myositis classification
More informationOutcome in Juvenile Rheumatoid Arthritis in India
Outcome in Juvenile Rheumatoid Arthritis in India Amita Aggarwal, Vikas Agarwal, Debasish Danda and Ramnath Misra From the Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences,
More informationAn autoimmune perspective on neuromuscular diseases
An autoimmune perspective on neuromuscular diseases Colin Chalk MD,CM FRCPC Montreal General Hospital McGill University Schlomchik 2001 The proportion of neuromuscular patients who have an autoimmune cause
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationReview Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis
Review Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis N. Pipitone, C. Salvarani Unità Operativa di Reumatologia, Arcispedale Santa Maria Nuova,
More informationComparison of Performance of ELISA with Indirect Immunofluoresence for the Testing of Antinuclear Antibodies
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 12 (2016) pp. 423-427 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.512.046
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationClinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139
More informationTitle: Why do patients with myositis die? A retrospective analysis of a single centre cohort.
Title: Why do patients with myositis die? A retrospective analysis of a single centre cohort. Authors: M Amaral Silva 1, E Cogollo 2, D Isenberg 3. M Amaral Silva and E Cogollo are regarded as equal first
More informationChronic focal polymyositis in the adult
Journal of Neurology, Neurosurgery, and Psychiatry, 1981, 44, 419-425 Chronic focal polymyositis in the adult N E BHARUCHA AND J A MORGAN-HUGHES From the Institute of Neurology, Queen Square, London S
More informationMyositis and Autoimmune ILD
Myositis and Autoimmune ILD 2018 AURA Annual Meeting Sedona, Arizona June 2, 2018 Chester V. Oddis, MD Director, Myositis Center University of Pittsburgh Disclosures Genentech: Clinical trial support Idera:
More informationIntravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
Send Orders for Reprints to reprints@benthamscience.ae The Open Rheumatology Journal, 2015, 9, 77-81 77 Open Access Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review
More informationThe idiopathic inflammatory myopathies
REVIEW Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD, and Ann M. Reed, MD Abstract Recently, there
More informationMalignancies in Korean Patients with Inflammatory Myopathy
Yonsei Medical Journal Vol. 47, No. 4, pp. 519-523, 2006 Malignancies in Korean Patients with Inflammatory Myopathy Sang-Won Lee, Sang Youn Jung, Min-Chan Park, Yong-Beom Park, and Soo-Kon Lee Division
More informationEXTENDED REPORT. Clinical and epidemiological research
Additional supplementary tables is published online only. To view the fi les please visit the journal online (http://ard.bmj.com/ content/71/6.toc). 1 Rheumatic Diseases Centre, Manchester Academic Health
More informationWhat are Autoantibodies and how do they work in Myositis?
What are Autoantibodies and how do they work in Myositis? Neil McHugh, University of Bath and Royal National Hospital for Rheumatic Diseases Orlando September 2015 Royal National Hospital for Rheumatic
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),
More informationIDIOPATHIC INFLAMMATORY MYOPATHY: CLINICOPATHOLOGICAL OBSERVATIONS IN THE INDIAN POPULATION
British Journal of Rheumatology ;3:83-83 IDIOPATHIC INFLAMMATORY MYOPATHY: CLINICOPATHOLOGICAL OBSERVATIONS IN THE INDIAN POPULATION BY M. L. PRASAD*t, C. SARKAR*, S. ROY*, U. BAGCHI*, R. R. SINGHf Y.
More informationAlternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Rheumatology Faculty Publications Medicine 3-15-2008 Alternative scoring of the cutaneous assessment
More information1 DOS CME Course 2011
Statin Myopathy February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation 1 Case 1 50 y/o woman with hyperlipidemia presents with one year history of deep
More informationTOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL
TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL Dr Augusto Vaglio, Dr Federica Maritati Unit of Nephrology, University Hospital of Parma, Via Gramsci 14, 43126 Parma
More informationHLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population
Gao et al. BMC Dermatology 2014, 14:9 RESEARCH ARTICLE Open Access HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population Xiang Gao 1,2,
More informationMuscle Pathology Surgical Pathology Unknown Conference. November, 2008 Philip Boyer, M.D., Ph.D.
Muscle Pathology Surgical Pathology Unknown Conference November, 2008 Philip Boyer, M.D., Ph.D. Etiologic Approach to Differential Diagnosis Symptoms / Signs / Imaging / Biopsy / CSF Analysis Normal Abnormal
More informationSerum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis
Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis L. Yuan 1, L. Yao 2, L. Zhao 1, L. Xia 1, H. Shen 1, J. Lu 1 1 Department of Rheumatology, First Affiliated
More informationEvolving Uses of IVIG in myositis
Evolving Uses of IVIG in myositis Rossitza I. Chichkova, MD, MS Associate Professor Depts of Neurology and Internal Medicine University of South Florida, Tampa, FL Immune Function In Normal State: Protects
More informationNew approaches to exercise Thursday Sep 4, 3 pm
New approaches to exercise Thursday Sep 4, 3 pm Helene Alexanderson, PhD, RPT Karolinska Institutet / Karolinska University Hospital, Stockholm, Sweden Erik G Svensson 04/09/2014 Helene Alexanderson 1
More informationValidation of Manual Muscle Testing and a Subset of Eight Muscles for Adult and Juvenile Idiopathic Inflammatory Myopathies
Arthritis Care & Research Vol. 62, No. 4, April 2010, pp 465 472 DOI 10.1002/acr.20035 2010, American College of Rheumatology ORIGINAL ARTICLE Validation of Manual Muscle Testing and a Subset of Eight
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More informationCLINICAL PRESENTATION
MYASTHENIA GRAVIS INTRODUCTION Most common primary disorder of neuromuscular transmission Usually due to acquired immunological abnormality Also due to genetic abnormalities at neuromuscular junction.
More informationA48-year-old Hispanic woman
Jamie Goodall, MS4, and Richard P. Usatine, MD University of Texas Health Science Center at San Antonio Skin rash and muscle weakness The patient s facial rash was spreading and she was having difficulty
More informationP olymyositis (PM) and dermatomyositis (DM) are systemic
297 EXTENDED REPORT Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis M Fathi, M Dastmalchi, E Rasmussen, I E Lundberg, G Tornling... See end of article
More informationClinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease
Rheumatology 2002;41:1268 1272 Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease H. Ihn, Y. Asano, M.
More informationMYOSITIS 101. Your guide to understanding myositis
MYOSITIS 101 Your guide to understanding myositis Patients who are informed, who seek out other patients, and who develop helpful ways of communicating with their doctors have better outcomes. Because
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationAssociated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study
e-issn 1643-3750 DOI: 10.12659/MSM.902016 Received: 2016.10.19 Accepted: 2016.11.17 Published: 2017.05.26 Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study Authors
More informationCritical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM. Andrzej Sladkowski
Critical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM Andrzej Sladkowski Potential causes of weakness in the ICU-1 Muscle disease Critical illness myopathy Inflammatory myopathy Hypokalemic
More informationHHS Public Access Author manuscript Expert Rev Clin Immunol. Author manuscript; available in PMC 2016 May 11.
Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Siamak Moghadam-Kia, Rohit Aggarwal, and Chester V Oddis * Department of Medicine, Myositis Center and Division of Rheumatology
More informationObjectives. Non-Traumatic Muscle Pathologies. Abnormal Muscle Signal Intensity. Inflammatory Myositis. Polymyostis / Dermatomyositis.
Non-Traumatic Muscle Pathologies Ali Naraghi Division of Musculoskeletal Radiology Joint Department of Medical Imaging University of Toronto Objectives Define the range of non-traumatic pathologies affecting
More information